Roche cuts UK price on cancer drug

Here's a strategy for penetrating the market when state healthcare won't yet pay for your drug: Cut the price. Roche is doing just that with Tarceva, its lung cancer treatment, until the UK's National Health Service committee determines whether to add Tarceva to its formulary.

Last month, the National Institute for Clinical Excellence rejected Tarceva, but an appeals panel questioned that decision. NICE has just agreed to reconsider--and this second appraisal could take up to a year.

- read the PharmaFocus article

Related Articles:
European committee gives negative ruling on Tarceva. Report
FDA panel endorses Tarceva for pancreatic cancer. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.